Successful treatment with alectinib after crizotinib-induced esophageal ulceration

Lung Cancer. 2015 Jun;88(3):349-51. doi: 10.1016/j.lungcan.2015.03.012. Epub 2015 Mar 20.

Abstract

Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration.

Keywords: Alectinib; Anaplastic lymphoma kinase (ALK); Crizotinib; Esophageal ulceration; Non-small-cell lung cancer (NSCLC).

Publication types

  • Case Reports

MeSH terms

  • Carbazoles / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / complications*
  • Carcinoma, Non-Small-Cell Lung / diagnosis
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Crizotinib
  • Endoscopes
  • Esophageal Diseases / chemically induced*
  • Esophageal Diseases / diagnosis
  • Female
  • Humans
  • Lung Neoplasms / complications*
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy*
  • Middle Aged
  • Piperidines / therapeutic use*
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles / adverse effects*
  • Pyrazoles / therapeutic use
  • Pyridines / adverse effects*
  • Pyridines / therapeutic use
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Ulcer / chemically induced*
  • Ulcer / diagnosis

Substances

  • Carbazoles
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • alectinib